NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9480	Companies
185562	Keywords
117963	Articles
99396	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/22/2025 at 12:30, 6 months 14 days ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. comments on the new COVID Vaccine Booster Shots policy adopted by the US FDA with focus on specific high-risk groups. Dr. Anil Diwan emphasizes evidence-based decision making for vaccine boosters

NanoViricides Inc. COVID Vaccine Booster Shots US FDA Policy Vaccine Effectiveness Dr. Anil Diwan
BRIEF

published on 05/16/2025 at 12:35, 6 months 20 days ago

NanoViricides fait progresser l'antiviral NV-387 dans les essais de phase II

Essai De Phase II Mise À Jour Financière Antiviral À Large Spectre Traitement MPox Épidémie De Rougeole
BRIEF

published on 05/16/2025 at 12:35, 6 months 20 days ago

NanoViricides Advances Antiviral NV-387 in Phase II Trials

Phase II Trial Financial Update Broad-spectrum Antiviral MPOX Treatment Measles Outbreak
PRESS RELEASE

published on 05/16/2025 at 12:30, 6 months 20 days ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 6 months 22 days ago

NanoViricides progresse avec le médicament antiviral à large spectre NV-387

Médicaments Antiviraux Traitement MPox Épidémie De Rougeole Développement NV-387 Stratégie Mondiale En Matière De Santé
BRIEF

published on 05/14/2025 at 12:35, 6 months 22 days ago

NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

Antiviral Drugs MPOX Treatment Measles Outbreak NV-387 Development Global Health Strategy
PRESS RELEASE

published on 05/14/2025 at 12:30, 6 months 22 days ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 6 months 28 days ago

Approbation de l'essai clinique de phase II du NV-387 de NanoViricides en RDC

NV-387 Essai Clinique Mpox Médicament Antiviral République Démocratique Du Congo
BRIEF

published on 05/08/2025 at 12:35, 6 months 28 days ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 6 months 28 days ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease

Accesswire

Published on 12/05/2025 at 23:30, 14 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 22:50, 54 minutes ago

Banyan Gold Grants Incentive Stock Options
Published on 12/05/2025 at 21:45, 1 hour 59 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 2 hours 14 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 2 hours 24 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 1 hour 28 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 1 hour 32 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 4 hours 46 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 5 hours 18 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 5 hours 29 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 44 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 44 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 44 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 44 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 6 hours 26 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE